Enter your email address:

Delivered by FeedBurner

Covid-19: No near-term threat to pharma cos' credit profile'

If the virus outbreak isn't contained over the next three months,
supply disruption is likely to be far greater than that in FY17,
resulting in pressures on cash flows for players. But the pressure
will be less on API players. Given the low degree of backward
integration, the report believes half companies may face pressures on
their credit metrics.



Post a Comment